News | August 14, 2024
Marksans Pharma Q1 FY25 revenue up 18%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
US business grew by +12.8% YoY
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
